

A wider pathological network underlying breathlessness and respiratory failure in amyotrophic lateral sclerosis

Kyle T S Pattinson and Martin R Turner.

Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK

kyle.pattinson@nda.ox.ac.uk

martin.turner@ndcn.ox.ac.uk

The adult-onset neurodegenerative disorder amyotrophic lateral sclerosis (ALS) is characterized by progressive dysfunction of upper motor neurons of the corticospinal tract, brainstem nuclear and lower motor neurons of the spinal cord anterior horns. There is clinicopathological and genetic overlap with frontotemporal dementia, and an emerging view of ALS as a syndrome (1). The majority of patients present with either focal limb or bulbar muscle weakness, which then spreads at a variable rate to other body regions (2). Median survival in ALS is 30 months from symptom onset, with most deaths associated with type II respiratory failure (3). In the majority of ALS patients, respiratory failure emerges insidiously after a variable period of progressive limb or bulbar muscle weakness. Symptoms are highly variable but include breathlessness, often with orthopnoea, sleep fragmentation (with nocturnal desaturations detectable on oximetry), daytime somnolence and other systemic symptoms associated with chronic hypercapnia.

The novel study by Georges and colleagues on in this issue of the *European Respiratory Journal* studied higher cerebral activity in ALS patients with respiratory failure (4). The authors raise the possibility that cortically-driven responses to

diaphragm weakness, and which are also associated with accessory muscle activation, might have the undesirable effect of increasing breathlessness. In a technically challenging study, a small group of ALS patients with respiratory failure underwent electroencephalography to detect pre-inspiratory responses (PIPs), along with electromyography of inspiratory neck muscles, during both spontaneous breathing and when using non-invasive ventilation (NIV). The authors noted that NIV appeared to attenuate the PIPs found in more than half of patients during spontaneous breathing. These PIPs were identified in the Cz position, most likely reflecting brain activity in sensory and motor areas. NIV also reduced the inspiratory neck muscle activity seen in all patients, and importantly also their breathlessness.

NIV prolongs survival as well as improving the symptoms of respiratory insufficiency in ALS, including breathlessness (5). Diaphragm weakness is assumed to be a principal driver of respiratory insufficiency in ALS, with orthopnoea very common in the advanced stages. An accurate measure of diaphragm strength using oesophageal pressure has been correlated with survival in ALS (6). Other studies have shown use of accessory muscles are a sensitive and specific surrogate marker for diaphragm weakness (7), with a specific link to the electromyographic detection of denervation in paraspinal muscles (8). Vital capacity is the commonly used surrogate to identify ALS patients developing respiratory failure in the clinic, though sniff nasal pressure has been shown to be more sensitive, and is particularly useful for those with bulbar dysfunction (9).

ALS is associated with widespread cortical and brainstem pathology, but less is known about the relative contribution of the wider respiratory control network in ALS, with the suggestion that there may be compensatory neuronal plasticity (10). Sleep-

disordered breathing is common in ALS and appears driven by central apnoeic events (11). Lesions of the central pattern-generating neurons of the brainstem pre-Bötzinger complex produce similar deficits (12), though this region has not yet been the subject of dedicated study in ALS.

The authors are clear about the limitations of their study, principally use of a small patient group with symptomatically advanced disease. The six patients in this study who did not show PIPs were generally more impaired, with longer disease duration and more severe respiratory impairment, but reported less breathlessness. The authors can only speculate whether this sub-group has decompensated, suffered an effect of more chronic NIV use, or have an unrelated basis for what is increasingly recognized to be a clinically heterogeneous syndrome.

Cortical activity in relation to sleep-disordered breathing in ALS is an obvious area that this study offers new avenues for exploration, and potentially modulation. It has been suggested that the only licensed, modestly disease-modifying drug for ALS, namely Riluzole, might have a specific beneficial role in modulating sleep-disordered breathing based on effects on neuronal rhythmicity in rodent models (13).

The authors identify the need to explore the relationship of their findings with the expanding awareness of frontotemporal cognitive and behavioural cortical deficits inherent to this multi-system neurodegenerative disorder. Breathlessness is likely to worsen already impaired cognitive performance via reallocation of limited attentional resources (14). This may be relevant in other respiratory disorders, in chronic obstructive pulmonary disease (COPD) there is some evidence that pulmonary rehabilitation improves cognitive performance (15), which may be partly due to

improvements in breathlessness. Therefore the link between breathlessness and cognitive dysfunction is particularly worthy of further investigation.

More broadly, there is increasing realisation that the sensation and impact of breathlessness is considerably more complex than simply increased neural traffic between the lungs and the sensory cortex (16-18). Abnormal respiratory signaling is shaped by a variety of emotional and psychological processes in different parts of the brain, the interactions of which lead to the sensations of breathlessness. Drawing a parallel from COPD, there is mounting evidence that many of the beneficial effects of pulmonary rehabilitation derive from relieving breathlessness-anxiety rather than the physical sensations of breathlessness (19, 20). Thus in the context of ALS a potential beneficial strategy may be to consider breathlessness-anxiety independently especially once medical therapy is optimised (21). Observations on breathlessness-anxiety in COPD suggest that fear conditioning related to learned negative associations between everyday situations and dyspnoea exacerbate the downward spiral of breathlessness and inactivity. Neuroimaging studies testing this are starting to emerge (22,23), and implicate emotional processes in the medial prefrontal cortex contributing to chronic breathlessness. Whether neurodegeneration in frontal and other emotion-processing brain regions specifically contributes to breathlessness in ALS remains unknown. In the present dataset, it is clear that NIV successfully attenuated the affective dimensions of breathlessness, presumably reducing the work of breathing to such an extent that the PIPs disappeared.

Measurements of the affective components of breathlessness combined with neurophysiology and neuroimaging have great potential to help individualise the treatment of dyspnoea and have potential as a powerful stratification tool, whether it

be ALS, COPD, cancer or asthma. Notably, this study quantitatively examined the subjective impact of breathlessness. The authors used the recently developed Multi-dimensional Dyspnea Profile (MDP) (24) revealing measurable breathlessness-anxiety in both groups during spontaneous breathing which was relieved by NIV. These findings echo those of a qualitative study (25).

Although the MDP has been designed primarily as a research tool (24), an alternate approach for clinical (and research) use is the Dyspnea-12 (D-12) questionnaire (26). The D-12 can be split into affective and physical components. The D-12 has been validated in clinical practice with a minimally clinical important difference (MCID) of 3 units (27) for the overall score. A detailed comparison of the two instruments is discussed by Banzett and colleagues (24). To fully evaluate how measuring the affective component of breathlessness will benefit patients, wider use of instruments such as these is now necessary in clinical practice, in conjunction with clinical research and quality improvement projects.

Future research using EEG or functional neuroimaging (28) might specifically address the mechanisms by which emotions influence breathlessness processing in ALS, with the potential for novel therapeutic or palliative strategies. Thus the study of Georges and colleagues broadens our insight into the neural networks underpinning the respiratory control system, and may lead to a deeper understanding of the neurophysiology of breathlessness across more diverse range of pathology.

References

1. Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. *Journal of neurology, neurosurgery, and psychiatry*. 2015;86(6):667-73.
2. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. *Lancet*. 2011;377(9769):942-55.
3. Kurian KM, Forbes RB, Colville S, Swingler RJ. Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. *Journal of neurology, neurosurgery, and psychiatry*. 2009;80(1):84-7.
4. Georges M, Moraviec E, Raux M, Gonzalez-Bermejo M, Pradat P, Similowski T, Morélot-Panzini C. Cortical drive to breathe in amyotrophic lateral sclerosis: a dyspnoea-worsening defense? *European Respiratory Journal*. 2016; 47: 1818–1828.
5. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. *Lancet neurology*. 2006;5(2):140-7.
6. Vitacca M, Clini E, Facchetti D, Pagani M, Poloni M, Porta R, et al. Breathing pattern and respiratory mechanics in patients with amyotrophic lateral sclerosis. *The European respiratory journal*. 1997;10(7):1614-21.
7. Lechtzin N, Wiener CM, Shade DM, Clawson L, Diette GB. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. *Chest*. 2002;121(2):436-42.
8. de Carvalho M, Pinto S, Swash M. Association of paraspinal and diaphragm denervation in ALS. *Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases*. 2010;11(1-2):63-6.

9. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. *Brain : a journal of neurology*. 2001;124(Pt 10):2000-13.
10. Nichols NL, Van Dyke J, Nashold L, Satriotomo I, Suzuki M, Mitchell GS. Ventilatory control in ALS. *Respiratory physiology & neurobiology*. 2013;189(2):429-37.
11. Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. *Neurology*. 2001;57(11):2040-4.
12. McKay LC, Janczewski WA, Feldman JL. Sleep-disordered breathing after targeted ablation of preBotzinger complex neurons. *Nature neuroscience*. 2005;8(9):1142-4.
13. Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? *CNS neuroscience & therapeutics*. 2011;17(1):4-31.
14. Eccleston C, Crombez G. Pain demands attention: a cognitive-affective model of the interruptive function of pain. *Psychol Bull*. 1999;125(3):356-66.
15. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. *The European respiratory journal*. 2010;35(4):913-22.
16. Hayen A, Herigstad M, Pattinson KT. Understanding dyspnea as a complex individual experience. *Maturitas*. 2013;76(1):45-50.
17. Herigstad M, Hayen A, Wiech K, Pattinson KT. Dyspnoea and the brain. *Respir Med*. 2011;105(6):809-17.
18. Pattinson KT, Johnson MJ. Neuroimaging of central breathlessness mechanisms. *Curr Opin Support Palliat Care*. 2014;8(3):225-33.

19. Carrieri-Kohlman V, Gormley JM, Eiser S, Demir-Deviren S, Nguyen H, Paul SM, et al. Dyspnea and the affective response during exercise training in obstructive pulmonary disease. *Nursing research*. 2001;50(3):136-46.
20. Herigstad M, Hayen A, A R, Pattinson KTS. Development of a dyspnoea word cue set for studies of emotional processing in COPD. *Respiratory Physiology and Neurobiology*. 2016;223:37-42.
21. Currow DC, Abernethy AP, Allcroft P, Banzett RB, Bausewein C, Booth S, et al. The need to research refractory breathlessness. *The European respiratory journal*. 2016;47(1):342-3.
22. Herigstad M, Hayen A, Evans E, Hardinge FM, Davies RJ, Wiech K, et al. Dyspnea-Related Cues Engage the Prefrontal Cortex: Evidence From Functional Brain Imaging in COPD. *Chest*. 2015;148(4):953-61.
23. Faull OK, Jenkinson M, Ezra M, Pattinson KT. Conditioned respiratory threat in the subdivisions of the human periaqueductal gray. *Elife*. 2016;5.
24. Banzett RB, O'Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, Meek PM, et al. Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research. *The European respiratory journal*. 2015;45(6):1681-91.
25. Gysels MH, Higginson IJ. The lived experience of breathlessness and its implications for care: a qualitative comparison in cancer, COPD, heart failure and MND. *BMC Palliat Care*. 2011;10:15.
26. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. *Thorax*. 2010;65(1):21-6.
27. Yorke J, Lloyd-Williams M, Smith J, Blackhall F, Harle A, Warden J, et al. Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. *Support Care Cancer*. 2015;23(11):3373-84.

28. Pattinson K. Functional brain imaging in respiratory medicine. Thorax. 2015.